Alirocumab (Praluent) to lower LDL-cholesterol

Medical Letter on Drugs and Therapeutics

Volumn 57, Issue 1475, 2015, Pages 113-115

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EVOLOCUMAB; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ALLERGIC REACTION; AMNESIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; HYPERCHOLESTEROLEMIA; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES;

EID: 84939182947     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. NJ Stone et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889.
2. JG Robinson et al. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl):S18.
3. JG Robinson et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489.
4. H Bays et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 2015 June 1 (epub).